参考文献/References:
［1］Fihn SD,Blankenship JC,Alexander KP,et al.2014 acc/aha/aats/pcna/scai/sts focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American college of Cardiology/American heart association task force on practice guidelines,and the American association for thoracic surgery,preventive cardiovascular nurses association,society for cardiovascular angiography and interventions,and society of thoracic surgeons［J］.Journal of the American College of Cardiology,2014,64(18):1929-1949.
［2 ］GBD Causes of Death Collaborators.Global,regional,and national age-sex-specific mortality for 282 causes of death in 195 countries and territories,1980-2017:a systematic analysis for the Global Burden of Disease Study 2017［J］.Lancet (London,England),2018,392(10159):1736-1788.
［3］Morishita T,Uzui H,Nakano A,et al.Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile:a cross-sectional study in Japanese patients with stable angina pectoris［J］.Heart and Vessels,2018,33(11):1301-1310.
［4］卢红蓉,杜松.冠心病病因病机理论研究概述［J］.环球中医药,2015,8(2):186-189.
［5］李婵玉,李耀兵,王洪浩,等.冠心病气虚血瘀证的临床研究进展［J］.新疆中医药,2019,37(6):118-121.
［6］邹文娟.从《伤寒论》论冠心病心绞痛发病机理与防治［J］.四川中医,2020,38(5):42-44.
［7］党林林,张瑞芬.运用施今墨强心止痛对药治疗冠心病心绞痛的机理探析［J］.内蒙古中医药,2021,40(4):146-148.
［8］周广社.加味四妙勇安汤治疗热毒血瘀型心绞痛45例［J］.陕西中医,2009,30(10):1287-1288.
［9］杨威,张学进,郭勇.热毒血瘀证与炎症相关性研究进展［J］.中华中医药学刊,2010,28(10):2168-2171.
［10］张健荣,李民,孙学娟.温病热毒血瘀证证型治法探析［J］.中医研究,2013,26(11):8-12.
［11］赵庭勇.温病热毒血瘀证证治浅探［J］.湖北中医杂志,2010,32(6):58-59.
［12］陈可冀.血瘀证与活血化瘀治疗临床研究［C］//第六次全国中西医结合血瘀证及活血化瘀研究学术大会论文集.延吉,2005:16-19.
［13］程江雪.中药提取物组合物的专利信息分析及专利保护研究［D］.北京:北京中医药大学,2016.
［14］程江雪,唐志书,郭东艳,等.当归-赤芍配伍对热毒血瘀证模型大鼠的影响［J］.中国现代应用药学,2019,36(23):2894-2898.
［15］丁雯,钱大玮,刘培,等.不同提取溶剂对当归赤芍药对主要活性成分溶出率的影响［J］.中国中药杂志,2012,37(7):916-919.
［16］刘庆林.赤芍的临床配伍应用浅析［J］.光明中医,2009,24(1):131-132.
［17］赵翔凤,相光鑫,王加锋,等.当归功效主治及用药禁忌的本草考证［J］.中华中医药杂志,2020,35(5):2479-2482.
［18］王新苗,邸莎,王青,等.赤芍的临床应用及其用量探究［J］.吉林中医药,2019,39(8):1017-1020.
［19］王琳琳,丁安伟.赤芍总苷对大鼠血瘀证模型的影响［J］.南京中医药大学学报,2011,27(6):552-554.
［20］Dong XY,He ZL,Xiang GH,et al.Paeoniflorin promotes angiogenesis and tissue regeneration in a full-thickness cutaneous wound model through the PI3K/AKT pathway［J］.Journal of Cellular Physiology,2020,235(12):9933-9945.
［21］李彦程,王玲燕,李瑞,等.赤芍乙酸乙酯部位化学成分的研究［J］.中国中药杂志,2016,41(12):2255-2260.
［22］Wu HX,Chen JY,Wang QT,et al.Expression and function of β-arrestin 2 stimulated by IL-1β in human fibroblast-like synoviocytes and the effect of paeoniflorin［J］.International Immunopharmacology,2012,12(4):701-706.
［23］王飞,伍文彬,徐世军,等.赤、白芍对血瘀证动物模型内皮功能及血液流变学的影响［J］.中药药理与临床,2009,25(4):40-41.
［24］Fischer SPM,Brusco I,Brum ES,et al.Involvement of TRPV1 and the efficacy ofα-spinasterol on experimental fibromyalgia symptoms in mice［J］.Neurochemistry International,2020,134:104673.
［25］Ravikumar YS,Mahadevan KM,Manjunatha H,et al.Antiproliferative,apoptotic and antimutagenic activity of isolated compounds from Polyalthia cerasoides seeds［J］.Phytomedicine:International Journal of Phytotherapy and Phytopharmacology,2010,17(7):513-518.
［26］张小琼.裂苞铁苋菜和紫芫花的化学成分与活性研究［D］.武汉:华中科技大学,2010.
［27］Pan MH,Lin JH,Lin-Shiau SY,et al.Induction of apoptosis by penta-O-galloyl-β-d-glucose through activation of caspase-3 in human leukemia HL-60 cells［J］.European Journal of Pharmacology,1999,381(2/3):171-183.
［28］Ho LL,Chen WJ,Lin-Shiau SY,et al.Penta-O-galloyl-beta-D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1［J］.European Journal of Pharmacology,2002,453(2/3):149-158.
［29］Oh GS,Pae HO,Oh H,et al.In vitro anti-proliferative effect of 1,2,3,4,6-penta-O-galloyl-beta-d-glucose on human hepatocellular carcinoma cell line,SK-HEP-1 cells［J］.Cancer Letters,2001,174(1):17-24.
［30］Wang HF,Pang WH,Xu XS,et al.Cryptotanshinone attenuates ischemia/reperfusion-induced apoptosis in myocardium by upregulating MAPK3［J］.Journal of Cardiovascular Pharmacology,2021,77(3):370-377.
［31］Hao Y,Yuan HT,Yu HZ.Downregulation of miR-483-5p decreases hypoxia-induced injury in human cardiomyocytes by targeting MAPK3［J］.Cellular & Molecular Biology Letters,2020,25:20.
［32］张云,旦菊花,孙鑫,等.MAPKs信号通路在动脉粥样硬化发生发展中的调控作用［J］.现代生物医学进展,2017,17(5):968-970.
［33］Lee MY,Luciano AK,Ackah E,et al.Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates［J］.Proceedings of the National Academy of Sciences of the United States of America,2014,111(35):12865-12870.
［34］Lee MY,Gamez-Mendez A,Zhang JS,et al.Endothelial cell autonomous role of Akt1:regulation of vascular tone and ischemia-induced arteriogenesis［J］.Arteriosclerosis,Thrombosis,and Vascular Biology,2018,38(4):870-879.
［35］Feng QT,Li X,Qin X,et al.PTEN inhibitor improves vascular remodeling and cardiac function after myocardial infarction through PI3k/Akt/VEGF signaling pathway［J］.Molecular Medicine (Cambridge,Mass),2020,26(1):111.
［36］Zhou YH,Han QF,Gao L,et al.HMGB1 protects the heart against ischemia-reperfusion injury via PI3K/AkT pathway-mediated upregulation of VEGF expression［J］.Frontiers in Physiology,2019,10:1595.
［37］Quintanilla M,Brown K,Ramsden M,et al.Carcinogen-specificmutation and amplification of Ha-ras during mouse skin carcinogenesis［J］.Nature,1986,322(6074):78-80.
［38］Weis SM,Cheresh DA.Pathophysiological consequences of VEGF-induced vascular permeability［J］.Nature,2005,437(7058):497-504.
［39］Chen Y,Dawes PT,Packham JC,et al.Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis［J］.The Journal of Rheumatology,2011,38(5):802-809.
［40］Huang A,Qi X,Cui YM,et al.Serum VEGF:diagnostic value of acute coronary syndrome from stable angina pectoris and prognostic value of coronary artery disease［J］.Cardiology Research and Practice,2020,2020:6786302.